| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.35▼ | 1.49▼ | 1.43▼ | 0.94▲ | 1.00▲ |
| MA10 | 1.40▼ | 1.42▼ | 1.21▲ | 0.94▲ | 1.04▲ |
| MA20 | 1.47▼ | 1.18▲ | 1.03▲ | 0.95▲ | 1.15▲ |
| MA50 | 1.45▼ | 1.03▲ | 0.99▲ | 1.03▲ | 1.36▼ |
| MA100 | 1.24▲ | 1.02▲ | 1.02▲ | 1.17▲ | 1.39▼ |
| MA200 | 1.12▲ | 1.06▲ | 1.11▲ | 1.30▲ | 2.52▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.025▼ | 0.020▲ | 0.061▲ | 0.024▲ | 0.004▲ |
| RSI | 35.861▼ | 58.861▲ | 63.495▲ | 67.559▲ | 55.152▲ |
| STOCH | 6.289▼ | 69.757 | 84.215▲ | 17.999▼ | 19.425▼ |
| WILL %R | -86.000▼ | -41.750 | -40.255 | -41.384 | -41.384 |
| CCI | -124.746▼ | 11.166 | 64.189 | 361.489▲ | 67.021 |
| ▲ PSAR&MOM | $MRKR PSAR Switch Up + Momentum | Set Alert |
| ▲ RSI&MACD | $MRKR MACD cross and RSI above 55 | Set Alert |
| ▲ RSI&VOL | $MRKR RSI Cross Up and Volume | Set Alert |
| RSI | $MRKR RSI(14) Crossed Above 50 | Set Alert |
| ▲ MACD | $MRKR MACD(12,26,9) Crossed Above Signal Line | Set Alert |
| MA | $MRKR Price Crossed Above MA(200) | Set Alert |
| MA | $MRKR Price Crossed Above MA(50) | Set Alert |
| MA | $MRKR Price Crossed Above MA(26) | Set Alert |
| MA | $MRKR Price Crossed Above MA(13) | Set Alert |
| MA | $MRKR Price Crossed Above MA(7) | Set Alert |
| ▲ GAP | $MRKR Open Gap Up %5 | Set Alert |
| ▲ GAP | $MRKR Open Gap Up %3 | Set Alert |
| ▲ GAP | $MRKR Open Gap Up %2 | Set Alert |
| ▲ BREAK | $MRKR Price Breaks 30 Days High | Set Alert |
| ▲ BREAK | $MRKR Price Breaks 20 Days High | Set Alert |
| ▲ BREAK | $MRKR Price Breaks 10 Days High | Set Alert |
|
Thursday, November 19, 2026 05:30 AM
Merck & Co., Inc. (NYSE:MRK) is studying how its experimental personalized cancer vaccine might work across different tumor types, with kidney cancer data expected to help determine whether the ...
|
|
Thursday, November 19, 2026 04:09 AM
Merck and Isomorphic Labs signed an AI drug discovery collaboration targeting cancer, combining proprietary research data with AI-powered ...
|
|
Thursday, November 19, 2026 04:00 AM
Highly competitive grant award provides significant non-dilutive funding to support Phase 2 development of MT-601 in CAR-relapsed lymphoma CPRIT award builds on encouraging Phase 1 clinical results, ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 19/11/26 | 1.02 | 1.68 | 0.9842 | 1.32 | 35,585,430 |
| 18/11/26 | 0.8442 | 0.92 | 0.8347 | 0.8532 | 105,817 |
| 17/11/26 | 0.8711 | 0.903 | 0.8101 | 0.8366 | 203,051 |
| 16/11/26 | 0.8977 | 0.912 | 0.8201 | 0.8286 | 135,857 |
| 13/11/26 | 0.92 | 0.93 | 0.87 | 0.87 | 76,100 |
| 12/11/26 | 0.945 | 0.97 | 0.90 | 0.90 | 140,799 |
| 11/11/26 | 0.9503 | 0.9798 | 0.9402 | 0.9501 | 28,388 |
| 10/11/26 | 1.01 | 1.03 | 0.95 | 0.95 | 53,000 |
| 09/11/26 | 0.925 | 1.05 | 0.87 | 0.9904 | 231,449 |
| 06/11/26 | 0.90 | 0.95 | 0.89 | 0.89 | 50,400 |
|
|
||||
|
|
||||
|
|